Tenaya–Alnylam $1.13B Deal Targets Heart Disease Genes
South San Francisco, California — March 5, 2026 Tenaya Therapeutics and Alnylam Pharmaceuticals have announced a major research collaboration...
Gene Therapy
Bionano Showcases OGM Advances in Oncology Research
February 25, 2026 – San Diego, California, USA Bionano Genomics highlighted major scientific advancements in Optical Genome Mapping (OGM)...
Hemogenyx Raises Capital via Warrant Exercise
LONDON, U.K., Feb. 23, 2026 — Hemogenyx Pharmaceuticals PLC announced the exercise of warrants and subsequent issue of new...
Vectory Doses First Patient in Phase 1/2 ALS Trial
Amsterdam, Netherlands | February 9 2026 — Vectory Therapeutics has announced that the first participant has been dosed in...
Ultragenyx Gene Therapy Shows Durable Gains in MPS IIIA
NOVATO, Calif., February 3, 2026 — Ultragenyx Pharmaceutical Inc. has reported positive long-term clinical data for UX111, an investigational...
Sensorion Secures €60M to Advance Gene Therapies for Hearing Loss
MONTPELLIER, France | January 28, 2026 — Sensorion, a clinical-stage biotechnology company focused on hearing loss disorders, announced a...
Opus Initiates Gene Therapy Trial for MERTK Retinal Disease
Research Triangle Park, N.C. | January 27, 2026 — Opus Genetics, Inc., a clinical-stage biopharmaceutical company focused on inherited...
PulseSight Completes Phase I Dosing of PST-611 in Dry AMD
Paris, France | January 22, 2026 — PulseSight Therapeutics, a Paris-based clinical-stage biotechnology company, has announced the successful completion...
Phase 1 Gene Therapy Data Shows Promise in Stargardt Disease
MALVERN, Pa., January 12, 2026 — Ocugen, Inc. announced the peer-reviewed publication of positive Phase 1 GARDian1 clinical trial...
France Grants Compassionate Access to Gene Therapy LUMEVOQ®
December 22, 2025 | Paris, France — GenSight Biologics announced that France’s medicines safety authority has granted Compassionate Use...